These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2274 related items for PubMed ID: 15860262

  • 1. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J, Sommer A.
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [Abstract] [Full Text] [Related]

  • 2. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
    Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F.
    Cancer Res; 2005 Nov 15; 65(22):10585-93. PubMed ID: 16288052
    [Abstract] [Full Text] [Related]

  • 3. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 15; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 4. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T.
    Cancer Invest; 2007 Feb 15; 25(1):32-7. PubMed ID: 17364555
    [Abstract] [Full Text] [Related]

  • 5. Androgen axis in prostate cancer.
    Culig Z, Bartsch G.
    J Cell Biochem; 2006 Oct 01; 99(2):373-81. PubMed ID: 16598769
    [Abstract] [Full Text] [Related]

  • 6. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
    Fog CK, Christensen IJ, Lykkesfeldt AE.
    Breast Cancer Res Treat; 2005 May 01; 91(2):133-44. PubMed ID: 15868441
    [Abstract] [Full Text] [Related]

  • 7. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I, Blackwell K, Chen S, Slingerland J.
    Cancer Res; 2005 Jan 01; 65(1):18-25. PubMed ID: 15665275
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
    Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M.
    Cancer Res; 2001 Mar 01; 61(5):1919-26. PubMed ID: 11280747
    [Abstract] [Full Text] [Related]

  • 9. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO, Collett K, Tretli S, Akslen LA, Grotmol T.
    APMIS; 2009 Sep 01; 117(9):644-50. PubMed ID: 19703124
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
    He D, Falany CN.
    Prostate; 2007 Sep 01; 67(12):1318-29. PubMed ID: 17626250
    [Abstract] [Full Text] [Related]

  • 11. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
    Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M.
    Breast Cancer Res Treat; 2010 Feb 01; 119(3):575-91. PubMed ID: 19288272
    [Abstract] [Full Text] [Related]

  • 12. Steroid receptors and their role in the biology and control of breast cancer growth.
    Cordera F, Jordan VC.
    Semin Oncol; 2006 Dec 01; 33(6):631-41. PubMed ID: 17145341
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H.
    Cancer Gene Ther; 2000 Jul 01; 7(7):997-1007. PubMed ID: 10917202
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK, Marquez-Garban DC, Pietras RJ.
    Drug Resist Updat; 2005 Aug 01; 8(4):219-33. PubMed ID: 16054421
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK.
    Cancer Chemother Pharmacol; 2005 Nov 01; 56 Suppl 1():10-20. PubMed ID: 16273359
    [Abstract] [Full Text] [Related]

  • 19. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC.
    Endocr Relat Cancer; 2005 Jul 01; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [Abstract] [Full Text] [Related]

  • 20. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
    Yu S, Wang X, Ng CF, Chen S, Chan FL.
    Cancer Res; 2007 May 15; 67(10):4904-14. PubMed ID: 17510420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 114.